SOURCE: Xtalks

Xtalks Webinars

October 14, 2015 07:00 ET

Upcoming Webinar on Development & Validation of Ultrasensitive Simoa-Based Immunoassay Services

TORONTO, ON--(Marketwired - October 14, 2015) - On Tuesday, October 20, 2015, Xtalks will host a complimentary webinar on the development and validation of ultrasensitive Simoa-based immunoassay services. The one-hour session starting at 9am EDT (2pm BST/UK GMT +1) will feature Mark Roskey, VP/GM of Applications and Reagents at Quanterix, and Dominic Eisinger, Vice President of Sales and Marketing at Myriad RBM, as presenters.

Reliably detecting immune-modulating proteins in serum and plasma from normal individuals has historically been impossible due to the lack of sensitivity of conventional immunoassays. Quanterix and Myriad RBM are working together to change this paradigm via ultrasensitive, high quality immunoassay services that offer drug developers an unparalleled approach to clinical research.

Quanterix, the developer of single molecule arrays (Simoa) technology, will describe the use of Simoa for the detection of proteins at very low concentrations, capable of providing a 1000-fold improvement in sensitivity to proteins over conventional assays. We will review the scientific principles that allow counting individual protein molecules and we will demonstrate how the Simoa technology can be used to obtain remarkable improvements in sensitivity, which has enabled significant breakthroughs in several therapy areas.

Myriad RBM, a leader in immunoassay testing services, will describe validated Simoa-based assay services and how carefully designed calibrators and controls ensure quality, precision and accuracy. Examples of how these reproducible assays, offered as a service in Myriad RBM's CLIA certified lab, can measure proteins at the femtogram per mL level will be demonstrated by quantifying key immune modulating proteins, present at undetectable levels with conventional technology in serum and plasma, from normal and diseased subjects. In conclusion, we will show that the unprecedented sensitivity and reliability of these ultrasensitive immunoassay services have the potential to revolutionize clinical research in multiple therapeutic areas including immuno-oncology, autoimmune disorders, cardiovascular diseases and other research focusing on inflammatory processes.

To register or learn more about this complimentary event visit: Development & Validation of Ultrasensitive Simoa-based Immunoassay Services

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit: http://xtalks.com

For information about hosting a webinar visit: http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2015/10/13/11G067415/Images/Quanterix_Logo_350-1032175861865.jpg
Image Available: http://www.marketwire.com/library/MwGo/2015/10/13/11G067415/Images/myriadrbm_500_edit-1131344754463.jpg

Contact Information